NOVARESE,Inc. (JP:9160)
:9160
Japanese Market
Advertisement

NOVARESE,Inc. (9160) AI Stock Analysis

Compare
0 Followers

Top Page

JP:9160

NOVARESE,Inc.

(9160)

Select Model
Select Model
Select Model
Outperform 72 (OpenAI - 4o)
Rating:72Outperform
Price Target:
¥372.00
▲(9.09% Upside)
The overall stock score is driven primarily by a favorable valuation and positive technical indicators. While financial performance shows strong revenue growth, challenges with leverage and cash flow generation need addressing. The absence of earnings call data and corporate events does not impact the score significantly.

NOVARESE,Inc. (9160) vs. iShares MSCI Japan ETF (EWJ)

NOVARESE,Inc. Business Overview & Revenue Model

Company DescriptionNovarese, Inc. engages in the wedding and restaurant businesses in Japan and internationally. The company provides wedding-related services, including venue guidance, wedding day planning, food and gift selection, and day-of operations; operates dress shops under the NOVARESE and ECRUSPOSE brands, that sells and rents wedding dresses, tuxedos, and Japanese attire, as well as party dresses for wedding and reception attendees; operates wedding banquets and restaurants; and provides flower decoration, as well as photography and videography services for weddings, and other events and parties. It also involved in the operation of WEDO, system that supports marriage preparation; provision of gifts to bride, groom, and guests at the wedding reception; business support services; and advertising agency services, including advertising planning, visual photography, graphic design, production of promotional tools, media purchasing, and planning and management of PR events. The company was formerly known as Workaholic Co., Ltd. and changed its name to Novarese, Inc. in December 2002. Novarese, Inc. was founded in 2000 and is headquartered in Chuo, Japan.
How the Company Makes MoneyNOVARESE, Inc. generates revenue primarily through the sale of its proprietary therapeutic products and diagnostic services. The company has established key revenue streams from direct product sales to healthcare providers and institutions, as well as licensing agreements with pharmaceutical companies for its patented technologies. Additionally, NOVARESE engages in strategic partnerships with research organizations and healthcare systems, which not only enhances its research capabilities but also opens up new markets and distribution channels. Government grants and funding for research initiatives also contribute to the company's financial health, allowing for sustained innovation and development.

NOVARESE,Inc. Financial Statement Overview

Summary
NOVARESE, Inc. demonstrates strong revenue growth and improving profitability metrics, though it faces challenges with high leverage and cash flow generation. The company is on a positive trajectory, but needs to address its debt levels and enhance cash flow stability to ensure long-term financial health.
Income Statement
75
Positive
NOVARESE, Inc. shows a solid revenue growth rate of 3.9% TTM, with consistent improvements in EBIT and EBITDA margins. However, the net profit margin remains modest at 4.1%, indicating room for profitability enhancement. The company has successfully increased its gross profit margin over time, reflecting efficient cost management.
Balance Sheet
65
Positive
The company's debt-to-equity ratio is relatively high at 2.29, suggesting significant leverage. However, the return on equity is improving, currently at 9.5%, indicating effective use of equity to generate profits. The equity ratio is moderate, showing a balanced asset structure.
Cash Flow
60
Neutral
The free cash flow growth rate is negative at -8.8% TTM, indicating challenges in cash generation. The operating cash flow to net income ratio is healthy, suggesting good cash conversion, but the free cash flow to net income ratio indicates potential cash flow constraints.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue20.53B19.30B18.27B17.22B11.19B7.33B
Gross Profit11.52B10.86B10.18B10.14B6.40B3.40B
EBITDA3.93B3.82B3.91B4.93B2.93B-1.75B
Net Income899.56M663.90M942.27M1.66B374.02M-2.95B
Balance Sheet
Total Assets34.52B34.73B32.30B31.98B32.63B33.86B
Cash, Cash Equivalents and Short-Term Investments2.40B3.57B1.72B2.80B2.25B2.34B
Total Debt14.34B13.53B19.01B14.13B22.31B23.25B
Total Liabilities25.44B25.89B24.12B24.75B27.04B28.64B
Stockholders Equity9.08B8.85B8.18B7.23B5.59B5.22B
Cash Flow
Free Cash Flow2.27B2.50B1.02B3.26B2.15B-2.49B
Operating Cash Flow3.93B3.89B3.00B4.62B2.37B-912.07M
Investing Cash Flow-1.81B-1.45B-2.03B-1.34B-253.64M-1.58B
Financing Cash Flow-2.39B-621.47M-2.04B-2.73B-2.21B1.71B

NOVARESE,Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price341.00
Price Trends
50DMA
336.32
Positive
100DMA
326.94
Positive
200DMA
314.61
Positive
Market Momentum
MACD
1.86
Negative
RSI
56.00
Neutral
STOCH
82.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9160, the sentiment is Positive. The current price of 341 is above the 20-day moving average (MA) of 338.35, above the 50-day MA of 336.32, and above the 200-day MA of 314.61, indicating a bullish trend. The MACD of 1.86 indicates Negative momentum. The RSI at 56.00 is Neutral, neither overbought nor oversold. The STOCH value of 82.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9160.

NOVARESE,Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥11.21B9.254.32%25.26%65.66%
72
Outperform
¥8.65B9.5811.07%5.85%
69
Neutral
¥11.96B4.144.83%0.81%61.06%
69
Neutral
¥3.63B8.281.26%6.57%52.89%
67
Neutral
¥22.06B18.923.20%-1.02%-32.57%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
57
Neutral
¥2.70B21.34-3.96%-73.55%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9160
NOVARESE,Inc.
343.00
7.00
2.08%
JP:2196
ESCRIT Inc.
193.00
-7.00
-3.50%
JP:2198
IKK Holdings Co., Ltd
752.00
34.92
4.87%
JP:2424
Brass Corp.
635.00
98.13
18.28%
JP:2485
TEAR Corp.
475.00
63.26
15.36%
JP:4331
Take and Give. Needs Co., Ltd.
828.00
-5.07
-0.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025